Syndax Pharmaceuticals (SNDX) Free Cash Flow (2015 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Free Cash Flow of -$50.3 million for Q1 2026, up 47.1% year-over-year from -$34.2 million in Q1 2025, and up 27.61% quarter-over-quarter from -$69.5 million in Q4 2025.
Powered by 
Analysis
Syndax Pharmaceuticals (SNDX) Free Cash Flow (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Free Cash Flow history runs 12 years deep, the most recent figure standing at -$50.3 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 47.1% year-over-year to -$50.3 million; the TTM figure through Mar 2026 stood at -$278.2 million (up 2.9% YoY), while the FY2025 annual figure was -$323.2 million, down 17.56% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$50.3 million, up from -$69.5 million in the prior quarter.
- The five-year high for Free Cash Flow was -$22.9 million in Q4 2022, with the low at -$95.2 million in Q1 2025.
- The 5-year median for Free Cash Flow is -$50.3 million (2026), against an average of -$55.4 million.
- The sharpest annual moves came in 2022 and 2026: Free Cash Flow slumped 122.73% in 2022, then surged 47.1% in 2026.
- Syndax Pharmaceuticals' Free Cash Flow stood at -$22.9 million in 2022, then tumbled by 80.61% to -$41.3 million in 2023, then sank by 38.79% to -$57.4 million in 2024, then fell by 21.18% to -$69.5 million in 2025, then climbed by 27.61% to -$50.3 million in 2026.
- Business Quant data shows SNDX's Free Cash Flow at -$50.3 million in Q1 2026, -$69.5 million in Q4 2025, and -$70.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Syndax Pharmaceuticals | 1.83 Bn | 1.28 Bn | 60.67 Mn | -30.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -30.27 Mn |
| Mar 31, 2026 | -50.35 Mn |
| Dec 31, 2025 | -69.54 Mn |
| Sep 30, 2025 | -70.67 Mn |
| Jun 30, 2025 | -87.80 Mn |
| Mar 31, 2025 | -95.16 Mn |
| Dec 31, 2024 | -57.39 Mn |
| Sep 30, 2024 | -62.32 Mn |
| Jun 30, 2024 | -71.65 Mn |
| Mar 31, 2024 | -83.55 Mn |
| Dec 31, 2023 | -41.35 Mn |
| Sep 30, 2023 | -44.65 Mn |
| Jun 30, 2023 | -35.37 Mn |
| Mar 31, 2023 | -39.23 Mn |
| Dec 31, 2022 | -22.89 Mn |
| Sep 30, 2022 | -28.54 Mn |
| Jun 30, 2022 | -40.31 Mn |
| Mar 31, 2022 | -41.93 Mn |
| Dec 31, 2021 | 100.71 Mn |
| Sep 30, 2021 | -24.94 Mn |